1

Resolution No. 6/23-1 

ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES 

VACCINES FOR CHILDREN PROGRAM 

VACCINES TO PREVENT INFLUENZA

The purpose of this resolution is to (1) update the product table in the IIV component of the 

resolution, (2) update the eligible groups section of the LAIV component of the resolution, 

and (3) add/update the links in the contraindications and precautions section of both 

components of the resolution. 

VFC resolution 6/21-2 is repealed and replaced by the following: 

 

Inactivated Influenza Vaccine (IIV)

Eligible Groups

All children aged 6 months through 18 years. 

Recommended Vaccination Schedule and Intervals 

• 6 months through 8 years: 1 or 2 doses, as noted in the current ACIP recommendations 

• 9 through 18 years: 1 dose 

• Minimum Age: 6 months 

• Minimum interval between dose 1 and dose 2 (where applicable): 4 weeks

 

The table below lists the currently approved inactivated influenza vaccines in the VFC 

program, including the age indication for each vaccine. 

 

Brand Name Presentation Age Indication

Afluria (Quadrivalent) 0.5 mL pre-filled syringe > 36 months

Afluria (Quadrivalent) 5.0mL multi-dose vial > 6 months

Fluarix (Quadrivalent) 0.5 mL pre-filled syringe > 6 months

Flucelvax (Quadrivalent)* 0.5 mL pre-filled syringe > 6 months

Flucelvax (Quadrivalent)* 5.0mL multi-dose vial > 6 months

Flulaval (Quadrivalent) 0.5 mL pre-filled syringe > 6 months

Fluzone (Quadrivalent) 0.5mL prefilled syringe/single-dose vial > 6 months

Fluzone (Quadrivalent) 5.0mL multi-dose vial > 6 months

Note: The use of brand names is not meant to preclude the use of other comparable licensed vaccines.

*All IIVs and LAIV are egg-based, with the exception of Flucelvax Quadrivalent, which is cell culturebased. 
2

Recommended Dosage

Refer to product package inserts available at:

https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states 

Contraindications and Precautions

Contraindications:

1. For egg-based IIV: History of severe allergic reaction (e.g., anaphylaxis) to any 

component of the vaccine (other than egg) or after previous dose of any influenza 

vaccine. 

2. For cell culture-based IIV: history of severe allergic reaction (e.g., anaphylaxis) to cell 

culture-based IIV or any component of the vaccine.

Precautions:

1. Moderate or severe acute illness with or without fever

2. GBS within 6 weeks following a previous dose of influenza vaccine 

3. For cell culture-based IIV only: History of severe allergic reaction to any other 

influenza vaccine.

Details of contraindications and precautions can be found at Prevention and Control of 

Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on 

Immunization Practices — United States, 2022–23 Influenza Season | MMWR (cdc.gov). 

Live Attenuated Influenza Vaccine (LAIV)

Eligible Groups

All healthy, non-pregnant children and adolescents (those who do not have an underlying 

medical condition that predisposes them to influenza complications) aged 2 through 18 years.

Recommended Vaccination Schedule and Intervals

• 2 years through 8 years: 1 or 2 doses, as noted in the current ACIP recommendations 

• 9 through 18 years: 1 dose 

• Minimum Age: 2 years 

• Minimum interval between dose 1 and dose 2 (where applicable): 4 weeks

Recommended Dosage

Refer to product package insert.

Contraindications and Precautions

Contraindications and precautions can be found at: 

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the 

Advisory Committee on Immunization Practices — United States, 2022–23 Influenza Season | 

MMWR (cdc.gov). 
3 

[If an ACIP recommendation regarding influenza vaccination is published within 6 months 

following this resolution, the relevant language above (except in the eligible groups sections) 

will be replaced with the language in the recommendation and incorporated by reference to the 

URL.]

Adopted and Effective: June 21, 2023 

This document can be found on the CDC website at: 

https://www.cdc.gov/vaccines/programs/vfc/providers/resolutions.html